| lisdexamfetamine / Generic mfg. |
ACTRN12624001061527: Oral Lisdexamfetamine for the treatment of Acute Methamphetamine withdrawal (the OLAM trial): A randomised controlled trial |
|
|
| Not yet recruiting | 4 | 184 | | | St Vincent's Hospital Sydney, NHMRC | Acute methamphetamine withdrawal | | | | |
| Recruiting | 4 | 62 | | | University of Sydney, Shire International GmbH | Binge-Eating Disorder | | | | |
NCT01413165: Phase 4, Open Label, Multicentre, 2 Year Safety Study of Lisdexamfetamine Dimesylate in Children/Adolescents With ADHD |
|
|
| Not yet recruiting | 4 | 12 | Europe | Lisdexamfetamine dimesylate, SPD 489 | Maastricht University Medical Center, Shire Development LLC | Attention Deficit Disorder With Hyperactivity | 08/13 | 12/13 | | |
ACTRN12621000045819: An open-label trial of oral lisdexamfetamine for the treatment of acute methamphetamine withdrawal |
|
|
| Completed | 4 | 15 | | | St Vincent's Hospital Sydney, The National Centre for Clinical Research on Emerging Drugs | Acute methamphetamine withdrawal | | | | |
NCT03337646: Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism |
|
|
| Completed | 4 | 48 | Canada | Lisdexamfetamine Dimesylate, Vyvanse | JPM van Stralen Medicine Professional, Shire | Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder | 03/23 | 03/23 | | |
| Recruiting | 4 | 10 | US | Stimulant, Adderall, Concerta, Aptensio, Daytrana, Metadate, Quillivant, Ritalin, Focalin, Vyvanse | Matthew J O'Brien, PhD, BCBA-D | Attention Deficit Hyperactivity Disorder, Problem Behavior | 01/25 | 01/25 | | |
| Completed | 3 | 180 | | | University of New South Wales , National Health and Medical Research Council, Curran Foundation | Addiction, Methamphetamine dependence | | | | |
NCT03924193: Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Acute Treatment |
|
|
| Completed | 3 | 141 | US | Lisdexamfetamine Dimesylate, Cognitive-Behavioral Therapy, Combination LDX and Cognitive-Behavioral Therapy | Yale University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Binge-Eating Disorder, Obesity | 09/23 | 09/23 | | |
NCT03926052: Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance Treatment |
|
|
| Active, not recruiting | 3 | 80 | US | Lisdexamfetamine Dimesylate, Placebo | Yale University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Binge-Eating Disorder, Obesity | 12/24 | 12/24 | | |
NCT04599504: Pharmacological and Behavioral Treatment After Bariatric Surgery: Medication Change for Non-Responders (Stage 2b) |
|
|
| Enrolling by invitation | 2/3 | 60 | US | Lisdexamfetamine Dimesylate (Medication), Vyvanse, Placebo | Yale University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Loss-of-control Eating, Obesity/Overweight | 05/27 | 05/27 | | |
2017-001490-16: Treatment of Bulimia Nervosa, with and without simultaneous probable ADHD, with the stimulant medicine Lisdexamphetamin . Behandling av Bulimia Nervosa, med och utan samtidig sannolik ADHD, med den psykostimulerande medicinen Lisdexamfetamin. |
|
|
| Ongoing | 2 | 50 | Europe | Capsule, hard, Elvanse vuxen | Stockholms läns landsting, Stiftelsen Söderström-Königska sjukhemmet, Petrus och Augusta Hedlunds stiftelse | Bulimia Nervosa with and without simultaneous Attention Deficit Hyperactivity Disorder. Bulimia Nervosa med och utan samtidig Attention Deficit Hyperactivity Disorder., Bulimia Nervosa with and without simultaneous ADHD Bulimia Nervosa med och utan samtidig ADHD, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2022-001906-24: LAMAinDiab - comparison of 2 pharmacological therapies (lisdexamphetamine vs methylphenidate) for pediatric patients with ADHD and type 1 diabetes - a randomized crossover clinical trial LAMAinDiab – porównanie 2 terapii farmakologicznych (lisdeksamfetamina vs metylfenidat) dla pacjentów pediatrycznych z zespołem ADHD i cukrzycą typu 1 - randomizowane krzyżowe badanie kliniczne . |
|
|
| Not yet recruiting | 2 | 150 | Europe | Elvanse, Concerta, Capsule, hard, Prolonged-release tablet | Medical University in Lodz, Agencja Badań Medycznych | Patients with ADHD and type I diabetes. Pacjenci z ADHD i Cukrzycą typu I., Patients with ADHD and type I diabetes. Pacjenci z ADHD i Cukrzycą typu I., Not possible to specify | | | | |
NCT05854667: Clinical Trial of High Dose Lisdexamfetamine and Contingency Management in MA Users |
|
|
| Recruiting | 2 | 440 | Canada | Treatment as Usual plus Placebo, Contingency Management, Treatment as Usual plus Placebo plus Contingency Management, Treatment as Usual plus lisdexamfetamine (LDX-01), Treatment as Usual plus lisdexamfetamine (LDX-01) plus Contingency Management | Centre hospitalier de l'Université de Montréal (CHUM), Canadian Institutes of Health Research (CIHR) | Methamphetamine Abuse, Methamphetamine-dependence, Addiction, Substance, Addiction | 11/25 | 11/25 | | |
| Recruiting | 2 | 150 | Europe | parental training in behavior management, PT training, Lisdexamfetamine, LDX, Methylphenidate, MPH | Medical University of Lodz, Medical University of Silesia, Medical University of Gdansk, Institute of Medical Sciences of the University of Opole, Pediatric Center of the Central Clinical Hospital of the Medical University of Lodz | Attention Deficit Disorder with Hyperactivity, Diabetes Mellitus, Type 1 | 12/27 | 12/27 | | |
| Recruiting | 1 | 40 | US | Lisdexamfetamine Dimesylate, Lifestyle therapy | University of Minnesota | Obesity, Childhood | 11/28 | 11/29 | | |
| Completed | N/A | 632 | Europe | methylphenidate medication, N06BA04, Concerta, Ritalin, Equasym, Medikinet, atomoxetine medication, N06BA09, Strattera, lisdexamphetamine medication, N06BA12, Elvanse, guanfacine medication, C02AC02, Intuniv | Karolinska Institutet | Attention Deficit Disorder With Hyperactivity (ADHD) | 07/21 | 06/22 | | |
NCT04727476: The Use of Lisdexamfetamine for Children Aged 7-13 With Attention Deficit Disorders |
|
|
| Active, not recruiting | N/A | 413 | Europe | Lisdexamfetamine | Aarhus University Hospital, Takeda | Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, Hyperkinetic Disorder | 08/21 | 05/22 | | |
| Completed | N/A | 16 | Europe | Dexamfetamine Sulfate 5 Mg Oral Tablet, Tentin, Lisdexamfetamine Dimesylate, Elvanse, blood samples, vena puncture | Amsterdam UMC, location VUmc, ADHDcentraal | Adhd | 12/21 | 06/22 | | |
NCT05551689: FOCUS ADHD Mobile Health App for Adult ADHD Patients |
|
|
| Completed | N/A | 73 | RoW | Psychostimulant, Methilphenidate, Lisdexamfetamine, FOCUS ADHD App, mhealth app | Hospital de Clinicas de Porto Alegre, University of Sao Paulo | ADHD | 09/22 | 03/23 | | |
| Active, not recruiting | N/A | 20 | Europe | Lisdexamfetamine dimesylate, Vyvanse (Shire Pharmaceuticals Ltd.), Guanfacine Extended Release Oral Tablet, Intuniv (Shire Pharmaceuticals Ltd.), Placebo | King's College London, Shire | ADHD | 12/22 | 03/25 | | |
NCT03497169: Bariatric Surgery and Pharmacokinetics of Lisdexamphetamine |
|
|
| Completed | N/A | 12 | Europe | Lisdexamfetamine Dimesylate, Lisdexamfetamine, Vyvanse, Elvanse | Norwegian University of Science and Technology, St. Olavs Hospital, Volvat Medisinsk Senter Stokkan, Namsos Hospital, Alesund Hospital | Obesity, Morbid | 09/20 | 09/20 | | |
